$20.69
0.67% day before yesterday
NYSE, Dec 27, 09:50 pm CET
ISIN
US29082K1051
Symbol
EMBC

Embecta Stock price

$20.70
+0.11 0.53% 1M
+8.24 66.13% 6M
+1.77 9.35% YTD
+1.83 9.70% 1Y
-26.30 55.96% 3Y
-26.30 55.96% 5Y
-26.30 55.96% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.13 0.62%
ISIN
US29082K1051
Symbol
EMBC
Sector

Key metrics

Market capitalization $1.20b
Enterprise Value $2.56b
P/E (TTM) P/E ratio 15.29
EV/FCF (TTM) EV/FCF 128.41
EV/Sales (TTM) EV/Sales 2.28
P/S ratio (TTM) P/S ratio 1.07
P/B ratio (TTM) P/B ratio negative
Dividend yield 2.90%
Last dividend (FY24) $0.60
Revenue growth (TTM) Revenue growth 0.21%
Revenue (TTM) Revenue $1.12b
EBIT (operating result TTM) EBIT $282.10m
Free Cash Flow (TTM) Free Cash Flow $19.90m
Cash position $274.20m
EPS (TTM) EPS $1.35
P/E forward 9.64
P/S forward 1.09
EV/Sales forward 2.31
Short interest 4.31%
Show more

Is Embecta a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Embecta Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Embecta forecast:

1x Buy
25%
2x Hold
50%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Embecta forecast:

Buy
25%
Hold
50%
Sell
25%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,123 1,123
0% 0%
100%
- Direct Costs 394 394
6% 6%
35%
729 729
3% 3%
65%
- Selling and Administrative Expenses 326 326
20% 20%
29%
- Research and Development Expense 79 79
8% 8%
7%
325 325
25% 25%
29%
- Depreciation and Amortization 43 43
30% 30%
4%
EBIT (Operating Income) EBIT 282 282
24% 24%
25%
Net Profit 78 78
11% 11%
7%

In millions USD.

Don't miss a Thing! We will send you all news about Embecta directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Embecta Stock News

Neutral
GlobeNewsWire
9 days ago
PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET.
Positive
Seeking Alpha
25 days ago
Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, p...
Neutral
Seeking Alpha
about one month ago
Embecta Corp. (NASDAQ:EMBC ) Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP of IR Dev Kurdikar - President and CEO Jake Elguicze - CFO Conference Call Participants Marie Thibault - BTIG Operator Good day, and welcome to the Embecta Fourth Quarter of Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Please be advised th...
More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,100
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today